We are happy to announce that a new call for 50 funded observerships will open from 13th September to 20th October 2022. First visits of observers to ECCs are envisioned to happen in March 2023. Contact your target ECC and collect your endorsement letter!

The deadline for registration has been extended until September 9th for our upcoming course in Montisola, Italy. The course focuses on the multidisciplinary aspects of migration and health, including global strategies, prevention, management and more.

The BioMed Alliance in collaboration with ESC have organized a survey on potential issues in availability of medical devices. You are invited and encouraged to participate and share your experiences on this pressing issue. The survey is available until 18 September.

Don’t miss your chance to join our conference on the challenges, opportunities and current requirements for antimicrobial drug development to address antimicrobial resistance. The 2022 ESCMID/ASM Conference on Drug Development takes place in Dublin, Ireland on October 4-7, 2022.

The World Health Organization (WHO) is pleased to announce a call for expressions of interests from survivors and their caregivers to serve in the inaugural WHO Task Force of AMR Survivors. See the full call for expressions of interest online. Deadline to apply is 15 September 2022.

The European Commission has just recently published a comprehensive scientific review of all antimicrobials which was carried out in order to determine which classes or substance should be reserved for human use only, followed by the respective legal measures. You can read more below.

EMA’s Emergency Task Force advises on intradermal use of Imvanex / Jynneos against monkeypox. More information can be found here.

EMA starts review of conditional marketing authorisation application for Skycovion COVID-19 vaccine. Relevant information can be found here.

COVID-19 induced by SARS-CoV-2 continues to be a major threat for healthcare and fragile people. This update focuses on antivirals, monoclonal antibodies and other treatments proposed for patients with mild or moderate COVID-19 at risk for hospitalization or death.